Summary

Eligibility
for people ages 50-85 (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
study ends around

Description

Summary

This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.

Official Title

A Phase IIB, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

Keywords

Parkinsons Disease, Parkinson Disease, Prasinezumab

Eligibility

Locations

  • UCSF
    San Francisco California 94143 United States
  • Cedars Sinai Medical Center
    Los Angeles California 90048 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Hoffmann-La Roche
ID
NCT04777331
Phase
Phase 2 Parkinson's Disease Research Study
Study Type
Interventional
Participants
About 586 people participating
Last Updated